Theralase Technologies Inc. V.TLT

RE:Valuation of the anti-virus platform

[ScienceFirst]

COVID-19 doesn't go away.  We might find an interested partner.

 

March 30 - Experts say Quebec has entered a sixth wave of COVID-19 propelled by BA.2 subvariant

 

March 30 - US Senate scrambles to reach 15B$ funding deal for Covid vaccines, testing and treatment

 

The party is pushing for a quick deal, saying that any gap in funding would put the country at risk of being unprepared for new surges of Covid-19. The BA.2 omicron subvariant of the virus has now become the dominant strain of the disease in the U.S., the Centers for Disease Control and Prevention said Tuesday.

____________________________

ScienceFirst - (3/30/2022 11:45:12 AM)

Valuation of the anti-virus platform

Valuation of a anti-virus platform, considering this:

- we have proof-of-concept data conducted by PHAC’s National Microbiology Laboratory regarding the destruction of viruses, including: H1N1 Influenza, Zika and a Biological Safety Level (“BSL”)-2 coronavirus at low nanomolar (“nM”) concentrations. These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus.

_______________________

livermore2 - (9/13/2021 7:58:01 PM)

Who saw the news on Providence Therapeutics today

Sold COVID vaccine license for estimated 500M deal - 100M cash up front!!!


More on that deal, to be able to provide a potential valuation to TLT's anti-virus platform:

Sept. 13, 2021:

Providence Therapeutics Enters into Comprehensive Agreements with Everest Medicines to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Emerging Markets in Asia - Providence Therapeutics

 

• Providence and Everest enter into a 50/50 worldwide collaboration to jointly develop products in two additional indications, leveraging Providence’s cutting-edge mRNA technology
• Providence will receive $100 million USD upfront, up to 12% equity position in Everest based upon milestones, and future profit share and royalties

Transaction Terms

Under the terms of the transaction Agreements, Providence will receive the following considerations;

For COVID-19 vaccines:

• US$50 million in initial upfront payment to be paid in cash;

• In China and Singapore, up to US$100 million in profit-sharing on COVID-19 vaccines, and once profit share has reached an aggregate amount of US$100 million, mid to high single-digit royalties, and in Everest Territories outside of China and Singapore, mid-teens royalties on COVID-19 vaccine sales.

For Collaboration Products, Additional Products, and the mRNA technology platform:

• US$50 million in initial upfront payment to be paid in cash;

• Up to US$300 million in future milestone payments to be paid in newly-issued Everest stock, based on the achievement of certain technology transfer, manufacturing, preclinical, development and commercial milestones.

Sept. 14, 2021

Emergent Biosolutions Secures Multi-year Development and Manufacturing Agreement With Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B - Providence Therapeutics

The biotech has received some funding from the Canadian government as well as upfront payments from its Indian partner Biological E Limited. and Chinese partner Everest Medicines Limited. It now plans to seek a further $400m in funding, CEO Brad Sorenson tells Scrip in this audio interview.

Along with Biological E and its North American partners - Emergent BioSolutions, Inc. and Northern Therapeutics Inc.- Providence aims to produce 1-1.5 billion doses of its coronavirus vaccines.

In the interview, Sorenson also discusses vaccines against cancer that are part of Providence Therapeutics’ suite of mRNA products.